P N Mollee, K M Taylor, B Williams, D Taylor, R Rodwell. Show Affiliations »
Abstract
Entities: Disease
Mesh： See more » Antineoplastic Combined Chemotherapy Protocols/therapeutic useBiomarkers, Tumor/analysisBiomarkers, Tumor/geneticsChromosomes, Human, Pair 15/geneticsChromosomes, Human, Pair 15/ultrastructureChromosomes, Human, Pair 17/geneticsChromosomes, Human, Pair 17/ultrastructureCytarabine/administration & dosageDaunorubicin/administration & dosageDisease ProgressionEtoposide/administration & dosageFemaleHumansIdarubicin/administration & dosageKaryotypingLeukemia, Promyelocytic, Acute/drug therapyLeukemia, Promyelocytic, Acute/etiologyLeukemia, Promyelocytic, Acute/geneticsMaleMiddle AgedNeoplasm Proteins/analysisNeoplasm Proteins/geneticsOncogene Proteins, Fusion/analysisOncogene Proteins, Fusion/geneticsPolycythemia Vera/geneticsPolycythemia Vera/pathologyPreleukemia/geneticsPreleukemia/pathologyPrognosisRemission InductionThrombocythemia, Essential/geneticsThrombocythemia, Essential/pathologyThrombophilia/etiologyTranslocation, GeneticTretinoin/administration & dosage
Substances： See more » Biomarkers, TumorNeoplasm ProteinsOncogene Proteins, Fusionpromyelocytic leukemia-retinoic acid receptor alpha fusion oncoproteinCytarabineTretinoinEtoposideIdarubicinDaunorubicin
Year: 1999 PMID： 10214878 DOI： 10.1038/sj.leu.2401358
Source DB: PubMed Journal: Leukemia ISSN： 0887-6924 Impact factor: 11.528